IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
IceCure Medical's ProSense® cryoablation system was prominently featured at ECIO 2025 in Rotterdam, with a major focus on breast cancer treatment. The conference highlighted several key studies demonstrating ProSense®'s effectiveness:
The THERMAC trial showed 94% efficacy rate, 0% complications, and 95% of patients preferring cryoablation over traditional surgery. A study by Prof. Vogl demonstrated 2.9 years mean progression-free survival in 45 patients with 56 tumors.
Another significant study comparing treatment methods revealed that cryoablation combined with hormonal therapy achieved 94% tumor size reduction, outperforming both standalone treatments. The conference included hands-on device training sessions and expert exchanges, highlighting ProSense®'s growing adoption in European markets.
Il sistema di crioablazione ProSense® di IceCure Medical è stato protagonista all'ECIO 2025 di Rotterdam, con un focus principale sul trattamento del cancro al seno. La conferenza ha messo in luce diversi studi chiave che ne dimostrano l'efficacia:
Il trial THERMAC ha evidenziato un tasso di efficacia del 94%, zero complicazioni e il 95% dei pazienti ha preferito la crioablazione rispetto alla chirurgia tradizionale. Uno studio del Prof. Vogl ha mostrato una sopravvivenza media libera da progressione di 2,9 anni in 45 pazienti con 56 tumori.
Un altro studio importante che ha confrontato i metodi di trattamento ha rivelato che la crioablazione combinata con la terapia ormonale ha ottenuto una riduzione del 94% delle dimensioni del tumore, superando entrambe le terapie singole. La conferenza ha incluso sessioni pratiche di formazione sull'uso del dispositivo e scambi tra esperti, sottolineando la crescente adozione di ProSense® nei mercati europei.
El sistema de crioablación ProSense® de IceCure Medical fue destacado en ECIO 2025 en Róterdam, con un enfoque principal en el tratamiento del cáncer de mama. La conferencia resaltó varios estudios clave que demuestran la eficacia de ProSense®:
El ensayo THERMAC mostró una tasa de eficacia del 94%, 0% de complicaciones y el 95% de los pacientes prefirieron la crioablación sobre la cirugía tradicional. Un estudio del Prof. Vogl demostró una supervivencia libre de progresión media de 2,9 años en 45 pacientes con 56 tumores.
Otro estudio significativo que comparó métodos de tratamiento reveló que la crioablación combinada con terapia hormonal logró una reducción del tamaño del tumor del 94%, superando a ambos tratamientos por separado. La conferencia incluyó sesiones prácticas de entrenamiento con el dispositivo e intercambios entre expertos, destacando la creciente adopción de ProSense® en los mercados europeos.
IceCure Medical의 ProSense® 크라이오어블레이션 시스템은 2025년 로테르담에서 열린 ECIO에서 유방암 치료에 중점을 두고 크게 소개되었습니다. 이번 학회에서는 ProSense®의 효과를 입증하는 여러 주요 연구가 발표되었습니다:
THERMAC 임상시험은 94%의 효능률, 0% 합병증, 그리고 95%의 환자가 기존 수술보다 크라이오어블레이션을 선호한다는 결과를 보였습니다. Prof. Vogl의 연구에서는 45명의 환자 56개의 종양에 대해 평균 무진행 생존기간이 2.9년으로 나타났습니다.
또 다른 중요한 연구에서는 치료법을 비교한 결과, 호르몬 치료와 병행한 크라이오어블레이션이 94%의 종양 크기 감소를 달성하여 단독 치료법보다 우수한 효과를 보였습니다. 학회에서는 기기 실습 교육 세션과 전문가 교류도 진행되어 ProSense®가 유럽 시장에서 점점 더 널리 채택되고 있음을 강조했습니다.
Le système de cryoablation ProSense® d'IceCure Medical a été mis en avant lors de l'ECIO 2025 à Rotterdam, avec un accent majeur sur le traitement du cancer du sein. La conférence a présenté plusieurs études clés démontrant l'efficacité de ProSense® :
L'essai THERMAC a montré un taux d'efficacité de 94%, 0% de complications, et 95% des patients ont préféré la cryoablation à la chirurgie traditionnelle. Une étude du Professeur Vogl a démontré une survie sans progression moyenne de 2,9 ans chez 45 patients présentant 56 tumeurs.
Une autre étude importante comparant les méthodes de traitement a révélé que la cryoablation combinée à l'hormonothérapie a permis une réduction de 94% de la taille des tumeurs, surpassant les deux traitements pris isolément. La conférence a également inclus des sessions pratiques de formation sur l'appareil et des échanges entre experts, soulignant l'adoption croissante de ProSense® sur les marchés européens.
Das ProSense® Kryoablationssystem von IceCure Medical wurde auf der ECIO 2025 in Rotterdam prominent vorgestellt, mit einem Schwerpunkt auf der Behandlung von Brustkrebs. Die Konferenz hob mehrere wichtige Studien hervor, die die Wirksamkeit von ProSense® belegen:
Die THERMAC-Studie zeigte eine Wirksamkeitsrate von 94%, 0% Komplikationen und 95% der Patienten bevorzugten Kryoablation gegenüber der herkömmlichen Chirurgie. Eine Studie von Prof. Vogl zeigte eine mittlere progressionsfreie Überlebenszeit von 2,9 Jahren bei 45 Patienten mit 56 Tumoren.
Eine weitere bedeutende Studie, die Behandlungsmethoden verglich, ergab, dass die Kryoablation kombiniert mit Hormontherapie eine Tumorgrößenreduktion von 94% erreichte und damit beide Einzelbehandlungen übertraf. Die Konferenz beinhaltete praktische Schulungen am Gerät und Expertenaustausch, was die zunehmende Verbreitung von ProSense® auf den europäischen Märkten unterstreicht.
- 94% efficacy rate with zero complications in THERMAC trial
- 95% patient preference over traditional surgery
- 2.9 years mean progression-free survival in clinical study
- Combined therapy showed 94% tumor size reduction
- Growing adoption in European markets
- None.
Insights
ProSense cryoablation shows promising clinical data with high patient preference, building academic validation for non-surgical tumor treatment.
IceCure's significant presence at ECIO 2025 represents growing clinical interest in cryoablation for breast cancer treatment. Multiple independent studies featuring ProSense® delivered impressive results, including the THERMAC trial's
This high patient preference statistic is particularly meaningful as treatment selection increasingly incorporates patient choice in clinical decision-making. The technology addresses an important market gap between traditional surgical approaches and medical management options. Another study demonstrated
For medical device technologies, scientific visibility through multiple conference presentations helps build the academic foundation needed for clinical adoption. The consistency of positive outcomes across different research groups strengthens ProSense's positioning. However, it's worth noting these remain conference presentations rather than published peer-reviewed studies or regulatory milestones that typically drive more immediate commercial impact.
Multiple studies show ProSense effectively treats breast tumors with excellent safety profile and patient satisfaction, expanding options beyond surgery.
The clinical data presented at ECIO 2025 demonstrates meaningful treatment outcomes for ProSense® cryoablation across several independent investigations. Prof. Vogl's study showed a mean progression-free survival of 2.9 years in 45 patients with 56 treated tumors (mean diameter 1.6 cm) - providing important validation of treatment durability.
From a clinical adoption perspective, the THERMAC trial's patient experience data is particularly compelling. The
These findings are especially significant for specific patient populations, including those ineligible for surgery. For these patients who typically have treatment options, the reported
While these results support continued clinical investigation and adoption in appropriate settings, broader implementation would typically require incorporation into formal clinical guidelines, establishment of reimbursement pathways, and completion of larger confirmatory studies.
- Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session
- Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating
95% of patients said they would choose thermal ablation over breast conserving surgery - In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively
- Three hands-on device trainings, including ProSense®
"As minimally invasive technologies like ProSense® have advanced the science of cancer care, interventional oncology is becoming an increasingly viable and preferred pathway for the treatment of breast cancer in
ProSense® was featured in the following.
Two scientific sessions and one poster presentation presenting data from investigator-initiated studies that used ProSense® for breast cancer:
- Oral presentation and Q&A by Dr. Sophie M. Wooldrik of
the Netherlands , titled: Review of the indications and results of the different techniques of thermal ablation on breast tumors; The treatment of breast cancer with percutaneous thermal ablation – THERMAC; An open label phase 2 screening trial- Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of
94% , a complication rate of0% , and a100% treatment tolerance.94% of patients were very satisfied or satisfied with the thermal ablation technique, and95% of patients stated they would choose thermal ablation over breast conserving surgery. 41 women were enrolled in the study, which compared cryoablation to radiofrequency ablation and microwave ablation.
- Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of
- Oral presentation and Q&A by Professor Thomas J. Vogl of
Germany , titled: CT-guided cryoablation of primary breast cancer: Evaluation of efficacy and safety- Conclusion: Cryoablation is a safe and effective treatment for primary breast cancer. 45 patients with 56 tumors (mean diameter 1.6 ± 0.7 cm) were treated. The mean overall progression-free survival was 2.9 years (
95% with a confidence interval of 2.3-3.6).
- Conclusion: Cryoablation is a safe and effective treatment for primary breast cancer. 45 patients with 56 tumors (mean diameter 1.6 ± 0.7 cm) were treated. The mean overall progression-free survival was 2.9 years (
Poster presentation titled: Non-surgical treatment of breast cancer: a comparison of outcomes between cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients not eligible for surgery
- Conclusion: Cryoablation with hormonal therapy reduces tumor size and residual disease more effectively than hormonal therapy or cryoablation alone, making it a promising option for patients not eligible for surgery. 64 patients were not suitable for surgery, and a total of 73 tumors (mean 14.8 mm) were treated. Tumor size reduction was greatest in the cryoablation with hormone therapy (HT) group (
94% , mean-reduction of 15.4 mm), followed by cryoablation only (82% , mean reduction of 9.7 mm), and followed by HT only (43% , mean reduction of 4.6 mm).
ProSense® featured during ECIO's Hands-On Device Cryoablation Training Sessions.
The sessions were well attended, and the training was well received.
An in-booth expert exchange session at IceCure's booth was conducted on the perspectives of breast cancer cryoablation from breast surgeons and interventional oncologists by Dr. Wooldrik and Professor Vogl, who had also presented at the scientific sessions.
About ProSense®
The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that minimally invasive technologies such as ProSense have advanced cancer care; the belief that ProSense is the leading cryoablation system for early-stage breast cancer tumors on the market today; and the belief that there will likely be continued commercial adoption of ProSense® for indications, including breast cancer, in
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecures-prosense-featured-at-european-conference-on-interventional-oncology-with-an-emphasis-on-breast-cancer-cryoablation-302434222.html
SOURCE IceCure Medical
FAQ
What were the key results of the THERMAC trial for ICCM's ProSense cryoablation system?
How effective was ProSense cryoablation with hormonal therapy for breast cancer treatment?
What was the progression-free survival rate in Prof. Vogl's ProSense study?
Where and when was ProSense cryoablation technology presented at ECIO?
